Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow. About 30% of patients do not respond well to the first treatment. Current risk stratification systems such as the European LeukemiaNet (ELN) are used to guide treatment decisions, but they do not always accurately predict how patients will respond.

In this study, led by N2CR researchers Dr Zhou Jianbiao and Prof Chng Wee Joo, the team highlights the limitations of existing methods that rely mainly on genetics. They suggest that including additional information—such as changes that affect how genes are switched on or off (methylome profiling)—could help better predict treatment response and guide more effective treatment strategies for AML patients.

Click here to read more.